Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inheritable heart muscle disease that predominantly affects the right ventricle (RV) and predisposes to ventricular arrhythmias and sudden cardiac death (SCD).^[@R1]--[@R17]^

In the last three decades, there have been a significant number of studies defining the pathogenesis, genetic aspects, and clinical manifestations of the disease (See 'Etiology, pathogenesis, diagnosis and natural history' in the online-only Data Supplement). In 1994 and 2010, an International Task Force (ITF) document proposed guidelines for the standardized diagnosis of ARVC/D based on electrocardiographic (ECG), arrhythmic, morphological, histopathologic, and clinico-genetic factors.^[@R18],[@R19]^

The growing knowledge regarding arrhythmic outcome, risk factors, and life-saving therapeutic interventions, make it particularly timely to critically address and place into perspective the issues relevant to the clinical management of ARVC/D patients. The present ITF consensus statement is a comprehensive overview of currently used risk stratification algorithms and approaches to therapy, either pharmacological or nonpharmacological, which often poses a clinical challenge to cardiovascular specialists and other practitioners, particularly those infrequently engaged in the management of ARVC/D. This document should be regarded as a guide to clinical practice where rigorous evidence is still lacking, because of the relatively low disease prevalence and the absence of controlled studies. Recommendations are based on available data derived from nonrandomized and observational studies and consensus within the conference panellists. When development of prognostic-therapeutic algorithms was controversial, management decisions were recommended to be individualized.

Recommendation and level of evidence of specific management options were classified according to predefined scales, as outlined in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} (<http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx>). Because randomized studies are not available, most consensus recommendations on treatment of ARVC/D are based on data derived from follow-up registries and/or experts opinions (ie, level of evidence B or C).
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Risk Stratification
===================

The natural history of ARVC/D is predominantly related to ventricular electric instability which may lead to arrhythmic SCD, mostly in young people and athletes.^[@R2],[@R8],[@R10]^ In advanced disease, progression of RV muscle disease and left-ventricular involvement may result in right or biventricular heart failure.^[@R3],[@R4]^ The available outcome studies are based on small patients cohorts followed for a relatively short follow-up period (Table [3](#T3){ref-type="table"}).^[@R22]--[@R36]^ The estimated overall mortality rate varies among different studies, ranging from 0.08% per year during a mean follow-up of 8.5 years in the series by Nava et al ^[@R20]^ to 3.6% per year during a mean follow-up of 4.6 years in the series by Lemola et al.^[@R21]^
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The adverse prognosis of ARVC/D patients has been initially overestimated by reports from tertiary referral centres largely composed of patients referred because of their high-risk status or severe clinical manifestations requiring specialized therapeutic interventions, such as catheter ablation or implantable defibrillator (ICD).^[@R21],[@R27],[@R37],[@R38]^ Studies from community-based patient cohorts and clinical screening of familial ARVC/D reported a much lower overall annual mortality rates (\<1%).^[@R24],[@R30]--[@R32],[@R36],[@R39]^ These latter data provide a more balanced view of the natural history of ARVC/D, in which the disease may occur with no or relatively mild disability and without the necessity for major therapeutic interventions.^[@R10],[@R12]--[@R17]^ The mechanism of SCD in ARVC/D is cardiac arrest due to sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), which may occur as the first manifestation of the disease in young people without previous symptoms.^[@R2],[@R7],[@R40]^

Data from autopsy series and observational clinical studies on ARVC/D have provided a number of clinical predictors of adverse events and death. Table [3](#T3){ref-type="table"} reports the clinical variables identified as independent predictors of poor outcome including malignant arrhythmic events (ie, SCD, cardiac arrest due to VF, appropriate ICD interventions, or ICD therapy on fast VT/VF), non-SCD, or heart transplantation, which were found in at least one published multivariable analysis. Patients who have experienced sustained VT or VF are at highest risk of experiencing life-threatening arrhythmic events.^[@R22]--[@R24]^ Unexplained syncope has been associated with an increased arrhythmic risk in some but not in all studies.^[@R22],[@R25],[@R26]^ Of note, unexplained syncope is defined as a loss of consciousness that: (i) occurs in the absence of documented ventricular arrhythmias and/or circumstances clearly leading to reflex-mediated changes in vascular tone or heart rate such as a micturition, defaecation, cough, or other similar conditions; and (ii) remains unexplained after a detailed clinical evaluation aimed to exclude other cardiac or extracardiac causes.^[@R25]^

Other independent risk factors for adverse events include nonsustained VT on 24-h Holter monitoring';^[@R25],[@R26]^ dilation/dysfunction of RV, left ventricle (LV), or both;^[@R21],[@R22],[@R27]--[@R30],[@R39]^ male gender;^[@R31],[@R32]^ compound and digenic heterozygosity of desmosomal-gene mutations;^[@R32]^ young age at the time of diagnosis;^[@R22],[@R23]^ proband status;^[@R31]^ inducibility at programmed ventricular stimulation;^[@R26],[@R28],[@R33]^ amount of electroanatomic scar^[@R34]^ and electroanatomic scar-related fractionated electrograms;^[@R35]^ extent of T-wave inversion across precordial and inferior leads;^[@R23],[@R31],[@R36]^ low QRS amplitude^[@R36]^ and QRS fragmentation.^[@R36]^

Electrophysiological Study
==========================

Electrophysiological study (EPS) is a valuable diagnostic test for differential diagnosis between ARVC/D and idiopathic right ventricular outflow tract tachycardia and may provide useful information regarding the VT inducibility for optimization of detection/discrimination algorithms and effective antitachycardia pacing protocols in patients undergoing ICD implantation.^[@R11],[@R28]^ However, conflicting data exist concerning the role of inducibility of sustained VT or VF for prediction of long-term arrhythmic outcome in ARVC/D patients.^[@R22],[@R23],[@R25],[@R26],[@R33]^ Discrepancies between the study results may be explained by differences in arrhythmic endpoints (ie, life-saving versus any appropriate ICD discharge).

The largest multicentre studies on ARVC/D patients who received an ICD demonstrated that EPS is of limited value in identifying patients at risk of arrhythmic cardiac arrest because of its low predictive accuracy.^[@R22],[@R25]^ In these studies, the reported incidence of 'life-saving' ICD discharges for treatment of fast VT or VF did not differ significantly in patients who were and were not inducible at EPS, regardless of the specific indication for ICD implantation. The study by Corrado et al^[@R25]^ on the outcome of 106 ARVC/D patients receiving an ICD for primary prevention reported that the positive and negative predictive value of inducibility for VT or VF was 35 and 70%, respectively. In this study, the type of ventricular tachyarrhythmia inducible at the time of EPS (ie, VT or VF) did not predict a statistically different arrhythmic outcome over the follow-up. The North American Multidisciplinary study on 98 ARVC patients receiving an ICD confirmed that inducible VT or VF at preimplant EPS did not predict appropriate interventions on fast VT or VF during a mean follow-up of 3.3 years.^[@R23]^ On the contrary, in the cohort of ARVC/D patients reported in the Johns Hopkins studies, inducibility was the most significant independent predictor of appropriate ICD firing. However, in the study by Bhonsale et al ^[@R26]^ the positive and negative predictive values of inducibility were 65 and 75%, respectively, and a sizeable proportion of patients experienced ICD interventions during follow-up despite a lack of inducibility of VT/VF. Moreover, the predictive value of inducibility for 'life-saving' ICD discharges was not demonstrated by either univariate or multivariate analysis. In asymptomatic patients, Bhonsale et al ^[@R26]^ reported that the combination of ≥2 factors such as inducibility at EPS, proband status, nonsustained VT, and PVCs ≥1000/24 h, predicts an incremental risk of appropriate ICD interventions; however, a statistically significant association with life-saving shocks for treatment of rapid VT or VF has not been demonstrated. In the study by Saguner et al ^[@R33]^ inducible VT was an independent predictor of composite end point including cardiac death, heart transplantation, unstable VT/VF, and syncope.

According to available studies on ARVC/D patients, the protocol of programmed ventricular stimulation should include a minimum of two drive-cycle lengths and three ventricular extrastimuli while pacing from two RV sites (apex and RV outflow tract); inducibility is defined as the induction of either VF or sustained VT, ie, lasting \>30 s or requiring termination because of haemodynamic compromise.^[@R21],[@R22],[@R25],[@R41]^

Recent studies showed that demonstration and quantification of bipolar RV electroanatomic scar area^[@R34]^ as well as identification of scar-related fractionated electrograms and late potentials^[@R35]^ on endocardial voltage mapping during EPS may provide significant added value for arrhythmic risk assessment in ARVC/D. Because endocardial voltage mapping is an invasive, expensive, and highly operator-dependent technique with a significant risk of inaccurate interpretation of low-voltage recordings in areas of normal myocardium due to suboptimal catheter contact, it is not recommended as a routine diagnostic tool.

Recommendations
===============

1.  -- EPS should be considered in the diagnosis and/or evaluation of patients with suspected ARVC/D (class IIa).

2.  -- Programmed ventricular stimulation may be considered for arrhythmic risk stratification of asymptomatic ARVC/D patients (class IIb).

3.  -- Endocardial voltage mapping may be considered in the diagnostic and prognostic evaluation of ARVC/D patients (class IIb).

Follow-up
=========

Patients with ARVC/D should undergo lifelong clinical follow-up to periodically evaluate new onset or worsening of symptoms, progression of morphological and/or functional ventricular abnormalities, and ventricular arrhythmias in order to reassess the risk of SCD and optimize the treatment. Cardiac evaluation of affected patients including resting 12-lead ECG, echocardiography, 24-h Holter monitoring, and exercise testing (for detection of effort-induced ventricular arrhythmias) should be performed on a regular basis (every 1--2 years) depending on the age, symptoms, and disease severity.

Due to the age-related penetrance of ARVC/D, healthy gene carriers and family members should also be offered repeat clinical assessment (every 2--3 years), mostly during adolescence and young adulthood.

Therapy
=======

The most important objectives of clinical management of ARVC/D patients include: (i) reduction of mortality, either by arrhythmic SCD or death from heart failure; (ii) prevention of disease progression leading to RV, LV, or biventricular dysfunction and heart failure; (iii) improvement of symptoms and quality of life by reducing/abolishing palpitations, VT recurrences, or ICD discharges (either appropriate or inappropriate); and (iv) limiting heart failure symptoms and increasing functional capacity. Therapeutic options consist of lifestyle changes, pharmacological treatment, catheter ablation, ICD, and heart transplantation.

Lifestyle Changes
=================

A link has been established between SCD and intense exertion in young individuals with ARVC/D. Competitive sports activity has been shown to increase the risk of SCD by five-fold in adolescent and young adults with ARVC/D.^[@R42]^ Early (ie, presymptomatic) identification of affected athletes by preparticipation screening and their disqualification from competitive sports activity may be 'life-saving'.^[@R8],[@R43]^

In addition, physical exercise has been implicated as a factor promoting development and progression of the ARVC/D phenotype. Kirchhof et al

^[@R44]^ demonstrated that in heterozygous plakoglobin-deficient mice, endurance training accelerated the development of RV dilatation, dysfunction, and ventricular ectopy, suggesting that chronically increased ventricular load might contribute to worsening of the ARVC/D phenotype. It has been postulated that impairment of myocyte cell-to-cell adhesion may lead to tissue and organ vulnerability, which may promote myocyte death especially during mechanical stress, which occurs during competitive sports activity.^[@R45],[@R46]^ Studies in humans confirmed that endurance sports and frequent exercise increase age-related penetrance, risk of VT/VF, and occurrence of heart failure in ARVC/D desmosomal-gene carriers.^[@R47],[@R48]^

Recommendations
===============

1.  -- It is recommended that patients with a definite diagnosis of ARVD/C not participate in competitive and/or endurance sports (Class I).

2.  -- Patients with a definite diagnosis of ARVD/C should be restricted from participation in athletic activities, with the possible exception of recreational low-intensity sports (Class IIa).

3.  -- Restriction from competitive sports activity may be considered in ARVC/D family members with a negative phenotype, either healthy gene carriers (class IIa) or with unknown genotype (class IIb).

Pharmacological Therapy
=======================

Pharmacological options in ARVC/D treatment consist of antiarrhythmic agents, β-blockers, and heart failure drug therapy.

Antiarrhythmic Drugs
====================

The aim of antiarrhythmic drug (AAD) therapy in patients with ARVC/D is to improve the quality of life by preventing symptomatic ventricular arrhythmias. There are no prospective and randomized trials on AAD therapy in ARVC/D and systematic comparison of treatment strategies.

Moreover, the assessment of efficacy of specific AAD therapy is difficult because ARVC/D patients tend to have multiple arrhythmic events over time and drugs are often changed.^[@R41],[@R49]^ Available data are limited to case--control studies, retrospective analyses, and clinical registries. Hence, indication for AAD therapy and choice of drug are based on an empirical approach resulting from extrapolation from other diseases, personal experience, consensus, and individual decisions.

The available evidence suggests that amiodarone (loading dose of 400--600 mg daily for 3 weeks and then maintenance dose of 200--400 mg daily), alone or in combination with β-blockers, is the most effective drug for preventing symptomatic ventricular arrhythmias with a relatively low proarrhythmic risk even in patients with ventricular dysfunction, although its ability to prevent SCD is unproved.^[@R49]^ Corrado et al ^[@R22]^ reported that the majority of life-saving ICD interventions in high-risk patients occurred despite concomitant AADs, a finding supporting the concept that AAD therapy may not confer adequate protection against SCD.

Recommendations
===============

1.  -- AADs are recommended as an adjunct therapy to ICD in ARVC/D patients with frequent appropriate device discharges (class I).

2.  -- The use of AADs should be considered to improve symptoms in patients with frequent premature ventricular beats and/or nonsustained VT (class IIa).

3.  -- AADs may be considered as an adjunct therapy to catheter ablation without a back-up ICD in selected ARVC/D patients with recurrent, haemodynamically stable VT (class IIb).

4.  -- AAD treatment of asymptomatic ARVC/D patients without documented ventricular arrhythmias and healthy gene carriers is not recommended (class III).

Beta-blockers
=============

Ventricular arrhythmias and cardiac arrest in ARVC/D are frequently triggered by adrenergic stimulation and occur during or immediately after physical exercise.^[@R8],[@R40],[@R42],[@R47],[@R48]^ Autonomic dysfunction with increased sympathetic stimulation of ventricular myocardium and subsequent reduction of β-adrenoceptor density was demonstrated by Wichter et al ^[@R50],[@R51]^ with the use of radionuclide imaging and quantitative positron emission tomography.

The indication for the use of β-blocker drugs in ARVC/D relies on their proven efficacy to prevent effort-induced ventricular arrhythmias, their proven efficacy in heart failure management, and their potential but unproven ability to hinder myocardial disease progression by lowering RV wall stress.

Because studies are not available to compare the efficacy of individual β-blockers and to define the most effective dosage, we recommend using nonvasodilating β-blockers titrated to maximum tolerated dose for age and weight.

Recommendations
===============

1.  -- Beta-blocker therapy is recommended in ARVC/D patients with recurrent VT, appropriate ICD therapies, or inappropriate ICD interventions resulting from sinus tachycardia, supraventricular tachycardia, or atrial fibrillation/flutter with high-ventricular rate (class I).

2.  -- Beta-blocker therapy should be considered in all patients with ARVD/C irrespective of arrhythmias (class IIa).

3.  -- The prophylactic use of β-blockers in healthy gene carriers is not recommended (class III).

Preload-reducing Drug Therapy
=============================

Fabritz et al ^[@R52],[@R53]^ provided experimental evidence that ventricular preload-reducing therapy prevents or tempers the development of ARVC/D in genetically susceptible murine hearts. Therapy with furosemide and nitrates completely prevented training-induced development of RV enlargement and normalized VT inducibility, thereby rendering treated plakoglobin-deficient mice phenotypically indistinguishable from their trained wild-type littermates.

Preload-reducing drug therapy is not yet part of clinical practice because the results of the animal studies demonstrating its beneficial effects require validation in other ARVC/D models and patients.

Heart Failure and Antithrombotic Drug Therapy
=============================================

The prevalence of RV or biventricular dysfunction leading to progressive heart failure and death in ARVC/D is variable in the published series, mostly depending on the selection criteria of patients, whether referred for arrhythmias or heart failure.^[@R20]--[@R27],[@R30]--33,36,39,44,48,54,55^ Left-ventricular involvement was originally considered an end-stage complication of ARVC/D, occurring late during the disease course and leading ultimately to biventricular pump failure.^[@R3],[@R4]^ More recently, genotype--phenotype correlations have shown early and greater LV involvement in genetically predisposed ARVC/D patients.^[@R54]--[@R58]^

In ARVC/D, thromboembolic complications may result from intracardiac thrombus formation into ventricular aneurysms, sacculations, or ventricular dilatation due to either global or regional ventricular dysfunction. A retrospective study by Wlodarska et al ^[@R59]^ on 126 ARVC/D patients with severe RV dilatation reported a 0.5% annual incidence rate of thromboembolic complications during a mean follow-up period of 99±64 months.

Recommendations
===============

1.  -- For ARVC/D patients who developed right- and/or left-sided heart failure standard pharmacological treatment with angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, β-blockers, and diuretics is recommended (class I).

2.  -- Long-term oral anticoagulation is generally indicated for secondary prevention in patients with documented intracavitary thrombosis or venous/systemic thromboembolism (class I).

3.  -- For ARVC/D patients with asymptomatic RV and/or LV dysfunction treatment with angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers may be considered (class IIb).

4.  -- Prophylactic anticoagulation for primary prevention of thromboembolism on the basis of ventricular dilatation/dysfunction, either global or regional, is not recommended (class III).

Catheter Ablation
=================

Catheter ablation is a therapeutic option for ARVC/D patients who have VT. Fibrofatty replacement of RV myocardium creates scar regions that are regarded as arrhythmogenic substrate for VT. Ventricular tachycardia is the result of a scar-related macro-reentry circuit, similar to that observed in the postmyocardial infarction setting, which is suitable for mapping and interruption by catheter ablation. Catheter ablation may be guided by either conventional electrophysiological or substrate-based mapping during sinus rhythm.^[@R60]--[@R72]^

Fontaine et al ^[@R60],[@R62]^ first studied the effects of direct current fulguration and demonstrated the feasibility of VT ablation in ARVC/D. Subsequently, several studies have reported on acute and long-term results of endocardial catheter ablation of VT using radiofrequency current.^[@R63]--[@R73]^ Overall, acute success was achieved in 60% to 80% of patients, whereas the recurrence rates during long-term follow-up of 3 to 5 years were as high as 50% to 70% (online-only Data Supplement, Table S1). The high frequency of VT recurrences and the discrepancy between the successful acute results and the unfavourable long-term outcome have been explained by the progressive nature of the ARVC/D substrate (ie, fibrofatty scar), which predisposes to the occurrence of multiple reentry circuits and new arrhythmogenic foci over time.^[@R10],[@R68]^ Recently, studies have suggested that epicardial location of some VT reentry circuits, which reflects the propensity of ARVC/D lesion to originate and progress from the epicardium, may partly explain the failure of conventional endocardial mapping/catheter ablation. Garcia et al ^[@R70]^ first reported the feasibility and efficacy of epicardial catheter ablation in ARVC/D patients who underwent an epicardial approach after previously failed endocardial VT mapping/ablation procedures. In these patients, the extent of electroanatomical scar area at voltage mapping was larger on the epicardial side of the RV wall than on the endocardium. Complete success was achieved in 85% of cases (partial success in 92%) and 77% of patients were free of VT during 18 months of follow-up. Phillips et al ^[@R72]^ compared the efficacy of traditional electrophysiological VT mapping/catheter ablation with other strategies including substrate-based and epicardial catheter approaches. The recurrences of VT were significantly reduced irrespective of the mapping/ablation strategy. The cumulative freedom from VT following procedures using 3D-electroanatomical mapping and/or epicardial approach was significantly greater than conventional ablation, although the recurrence rates remain considerable. Freedom from VT after epicardial ablation of 64 and 45% at 1 and 5 years was found, which was significantly improved compared with studies using the endocardial approach. According to Berruezo et al,^[@R71]^ complete scar dechannelling with elimination of either endo or epicardial scar conducting channels (ie, intrascar, interscar, or between scar and valvular annuli) in addition to ablation of clinical VT is a promising approach to improve long-term success rate of catheter ablation.

According to available data, catheter ablation of VT in ARVC/D patients should be considered a potentially effective strategy for eliminating frequent VT episodes and ICD shocks rather than a curative therapeutic approach, until long-term efficacy has been consistently documented. Catheter ablation has not been proved to prevent SCD and should not be looked on as an alternative to ICD therapy in ARVC/D patients with VT, with the exception of selected cases with a drug refractory, haemodynamically stable, single morphology VT.^[@R22]^ Additional AAD therapy and repeated ablation procedures as well as back-up ICD implantation are required to provide clinical control of VT and SCD prevention.

Recommendations
===============

1.  -- Catheter ablation of VT is recommended in ARVC/D patients with incessant VT or frequent appropriate ICD interventions on VT despite maximal pharmacological therapy, including amiodarone (class I).

2.  -- An epicardial approach to VT ablation is recommended in patients who fail one or more attempts of endocardial VT ablation (class I).

3.  -- Catheter ablation of VT should be considered in ARVC/D patients with incessant VT or frequent appropriate ICD interventions on VT who have failed pharmacological therapy other than amiodarone (class IIa).

4.  -- A combined endocardial/epicardial VT ablation approach as an initial ablation strategy should be considered, provided that the operator and electrophysiological laboratory are experienced performing epicardial VT ablation in patients with ARVC/D (class IIa).

5.  -- Catheter ablation of VT may be considered in ARVC/D patients with incessant VT or frequent appropriate ICD interventions on VT who have not failed pharmacological therapy and who do not wish to be treated with pharmacological therapy (class IIb).

6.  -- Catheter ablation may be indicated as first choice therapy without a back-up ICD for selected patients with drug-refractory, haemodynamically stable, single-morphology VT (class IIb).

7.  -- Catheter ablation is not recommended as an alternative to ICD for prevention of SCD in ARVC/D (class III).

Implantable Defibrillator Therapy
=================================

Implantable defibrillator therapy is the most logical therapeutic strategy for patients with ARVC/D, because the natural history is primarily characterized by the risk of SCD and, only secondarily, by contractile dysfunction leading to progressive heart failure. Prospective randomized trials are currently not available for ethical reasons and because of practical limitations predominantly linked to relatively low disease prevalence and low event rate. The available data, coming from observational studies/registries of large populations of ARVC/D patients, have established efficacy and safety of ICD therapy.^[@R22],[@R25],[@R26],[@R28],[@R74]--[@R81]^ The main results of available studies on ICD therapy in ARVC/D are summarized in the online-only Data Supplement, Table S2. These studies consistently document that ICD successfully interrupts lethal ventricular tachyarrhythmias and improves long-term outcome of selected high-risk ARVC/D patients. Overall, between 48 and 78% of patients received appropriate ICD interventions during a mean follow-up period of 2 to 7 years after implantation. Many of these patients experienced multiple ICD discharges during this period and VT storm was not infrequently reported. In most studies, the survival benefit of the ICD was evaluated by comparing the actual patient survival rate with the projected freedom of ICD interventions for fast VT (\>240 bpm) or VF (ie, 'life- saving' ICD interventions), which were used as a surrogate for aborted SCD, based on the assumption that these tachyarrhythmias would have been fatal without termination by the device.^[@R22],[@R25],[@R28],[@R77]^ The end point was reached by device interrogation and review of stored electrocardiograms regarding ICD interventions in response to fast VT/VF during follow-up. In the largest multicentre study, the fast VT/VF-free survival rate was 72% at 36 months compared with the actual patient survival of 98%, with an estimated survival benefit of 26%.^[@R22]^ The largest single-center experience found an estimated improvement of overall survival of 23, 32 and 35% after 1, 3 and 7 years of follow-up, respectively.^[@R28]^ These results were confirmed by other series reporting rates of life-saving ICD interventions in 30% to 50% of patients during follow-up. Despite the relatively short follow-up of the available studies, the time between implantation and the first appropriate discharge was ≥1 year in a large proportion of patients with a maximal interval of 5.5 years.^[@R25],[@R26],[@R74]--[@R81]^ This finding suggests that ICD implantation is a lifelong preventive measure with life-saving interventions occurring even after particularly long phases of dormant ventricular electric instability.

It is important to recognize that survival benefit of ICD treatment is obtained at the expense of significant complications during follow-up, with estimated rates of lead/device related complications and inappropriate ICD therapies of 3.7%/yr and 4.4%/yr, respectively (online-only Data Supplement, Table S2). Detailed information on ICD-related complications in the published ICD studies is provided by the recent meta-analysis by Schinkel.^[@R82]^ In the long-term study (80±43 months) by Wichter et al,^[@R28]^ 37 of 60 (62%) ARVC/D patients had a total of 53 serious adverse events (31 lead-related), 10 occurring during the perioperative phase and 43 during follow-up. This high rate of lead-related adverse events may be explained by the peculiar ARVC/D pathobiology which leads to progressive loss of myocardium with fibrofatty replacement, also affecting the site of RV lead implantation. In this regard, Corrado et al reported that ≈4% of ARVC/D patients required an additional septal lead owing to loss of ventricular sensing/pacing functions at the apical RV free wall during a follow-up of 3.3 years.^[@R22]^ Therefore, particular attention should be paid to progressive loss of R-wave sensing amplitude during follow-up, which may compromise adequate device function and may indicate disease progression.

Inappropriate ICD interventions occur in 10% to 25% of patients with ARVC/D, mostly at young age,^[@R77]^ and are usually caused by sinus tachycardia or atrial tachyarrhythmia (online-only Data supplement, Table S2). Inappropriate interventions are painful and may have a profound clinical and psychological impact on patients.^[@R83]^ The incidence of inappropriate ICD discharges can be lowered by appropriate ICD programming^[@R84]^ and administration of β-blockers or sotalol. Although the use of dual-chamber detection algorithms offers the potential to reduce the number of inappropriate interventions by improving discrimination of ventricular from supraventricular arrhythmias, an additional lead in atrium predisposes to a higher incidence of early and late postoperative complications.

Indications for ICD Implantation
================================

The published studies on ARVC/D patients that provided information about the independent predictors for major arrhythmic events (ie, SCD, cardiac arrest due to VF, sustained VT, and appropriate ICD interventions) during follow-up (Table [3](#T3){ref-type="table"}), have been used to construct three categories of risk for SCD (high, intermediate, and low) that were determined by consensus (Figure). The recommendations for ICD implantation for each risk category were based not only on the statistical risk, but also on the general health, socioeconomic factors, the psychological impact and the adverse effects of the device.

![Flow chart of risk stratification and indications to ICD implantation in ARVC/D. Based on the available data on annual mortality rates associated to specific risk factors, the estimated risk of major arrhythmic events in the high-risk category is \>10%/yr, in the intermediate ranges from 1 to 10%/yr, and in the low-risk category is \<1%/yr. Indications to ICD implantation were determined by consensus taking into account not only the statistical risk, but also the general health, socioeconomic factors, the psychological impact and the adverse effects of the device. SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia; RV, right ventricle; and LV, left ventricle. \*See the text for distinction between *major* and *minor* risk factors.](cir-132-441-g004){#F1}

The *high-risk* category includes patients who experienced cardiac arrest due to VF or sustained VT. This group of patients has an estimated rate of life-threatening arrhythmic events \>10%/yr and most benefits for ICD therapy.^[@R22]--[@R24]^ A prophylactic ICD implantation is also recommended in patients with severe RV dysfunction (RV fractional area change ≤17% or RV EF ≤35%) or LV dysfunction (LV EF ≤35%) who are considered at high risk by consensus, even in the absence of life-threatening ventricular arrhythmias.^[@R21],[@R22],[@R27],[@R28],[@R30],[@R39]^ Because the specific arrhythmic risk of ventricular dysfunction is still undermined for patients with ARVC/D, the inclusion of this clinical variable into the high-risk category was based on extrapolation from other cardiomyopathies and personal experience.

The *low-risk* category comprises probands and relatives without risk factors as well as healthy gene carriers who show a low rate of malignant arrhythmic events (estimated annual event rate \<1%/year^[@R25],[@R31]^) over a long-term follow-up and do not require any treatment, including ICD therapy.

Between the two categories there are ARVC/D patients with ≥1 risk factors who are deemed to have an *intermediate risk* (estimated annual event rate between 1 and 10%^[@R25],[@R26]^). Among the consensus experts there was general agreement that syncope, non sustained ventricular tachycardia (NSVT), or moderate ventricular dysfunction, either RV (RV fractional area change between 24 and 17% or RV EF between 40 and 36%), or left-ventricular (LV EF between 45 and 36%), are 'major' risk factor that justify (weight of opinion in favor of ICD) a prophylactic ICD. On the other hand, there was general consensus that the other factors reported in Table [3](#T3){ref-type="table"} ('minor' risk factors) are associated with a risk of major arrhythmic events not sufficiently high (or controversial) to warrant systematic ICD implantation for primary prevention (weight of opinion against ICD). The decision to implant an ICD in patients of this category should be made on individual basis, by assessing the overall clinical profile, the age, the strength of the risk factor identified, the level of SCD risk that is acceptable to the patient, and the potential risk of inappropriate interventions and complications.

It is noteworthy that indications for ICD implantation may vary in different countries as a consequence of several nonclinical factors such as cultural background, socio-economic conditions, health system, availability of advanced technology, cost--benefit considerations, and liability. Compared with the conservative approach of many European countries, the current threshold for decision to implant an ICD in the USA is lower.^[@R13]^ It is particularly important to outline the potential risk of inappropriate ICD implants due to a false diagnosis of ARVC/D based on misinterpretation of imaging studies including cardiac magnetic resonance.^[@R85]^

Recommendations
===============

1.  -- Implantation of an ICD is recommended in ARVC/D patients who have experienced ≥1 episodes of haemodynamically unstable, sustained VT or VF (class I).

2.  -- Implantation of an ICD is recommended in ARVC/D patients with severe systolic dysfunction of the RV, LV, or both, irrespective of arrhythmias (class I).

3.  -- Implantation of an ICD should be considered in ARVC/D patients who have experienced ≥1 episodes of haemodynamically stable, sustained VT (class IIa).

4.  -- Implantation of an ICD should be considered in patients who have 'major' risk factors such as unexplained syncope, moderate ventricular dysfunction, or NSVT (class IIa).

5.  -- Implantation of an ICD may be considered in patients with 'minor' risk factors after a careful discussion of the long-term risks and benefits of ICD implantation (class IIb).

6.  -- Prophylactic ICD implantation is not recommended in asymptomatic ARVC/D patients with no risk factors or healthy gene carriers (class III).

Device Selection
================

A single-chamber ICD system is recommended in order to minimize the incidence of long-term lead-related complications, mostly in young patients.

Experience with ICD therapy consistently highlights the beneficial effect of antitachycardia pacing which is highly effective in terminating VT episodes in ARVC/D patients. The precise clinical role of leadless subcutaneous ICD in patients with ARVC/D remains to be defined. A decision whether to implant a leadless device needs to be patient specific, balancing lead-related complications with the likelihood of recurrent VT that may be effectively pace-terminated.

Additional cardiac resynchronization therapy appears reasonable for those ARVC/D patients with a LV EF ≤35% and a wide QRS with a left bundle-branch block pattern, even though clinical benefit is extrapolated from resynchronization therapy in other disease states.^[@R86]^ Right-ventricular resynchronization therapy has been proposed as a therapy for patients with congenital heart disease and chronic RV heart failure;^[@R87]^ however, no data are available concerning the clinical and haemodynamic effects of RV pacing in ARVC/D patients with RV dysfunction and a wide QRS with right bundle-branch block pattern.

Heart Transplantation
=====================

Arrhythmogenic right-ventricular cardiomyopathy/dysplasia patients with untreatable heart failure or uncontrollable ventricular tachyarrhythmias may require heart transplantation. Tedford *et al*.^[@R88]^ reported the Johns Hopkins Registry experience with 18 ARVC/D patients (61% males; mean age 40±14 year) undergoing heart transplantation. The most common indication for cardiac transplantation was heart failure, with less than one-third of patients receiving transplants for intractable ventricular arrhythmias. Patients who received heart transplants were significantly younger (mean age at the time of first symptoms 24±13 years) and had a more prolonged clinical course (time from first symptoms to transplant ≈15 years) compared with other ARVC/D registry participants. One-year after transplant, the survival was 94 and 88% of patients were alive at an average post-transplant follow-up of 6.2±4.8 years.

Heart transplantation is recommended as a final therapeutic option in ARVC/D patients with either severe, unresponsive congestive heart failure or recurrent episodes of VT/VF which are refractory to catheter (and surgical) ablation in experienced centres and/or ICD therapy.

Other Surgical Therapies
========================

There is currently no clinical role of surgical therapies such as RV cardiomyoplasty,^[@R89]^ RV disarticulation,^[@R90]^ beating heart cryoablation,^[@R91]^ and left cardiac sympathetic denervation^[@R92]^ in the treatment of patients with ARVC/D.

Conclusions
===========

The therapeutic management of patients with ARVC/D has evolved over the years and continues to be an important challenge. To further improve risk stratification and treatment of patients, more information is needed on the natural history, long-term prognosis, and risk assessment. Special attention should be focused on the identification of patients who would benefit from ICD implantation in comparison to pharmacological and other nonpharmacological approaches. Data from prospective studies/registries with larger number of patients and longer follow-up as well as data obtained from multicentre randomized controlled trials are required to provide evidence-based recommendations for the best care of ARVC/D patients.

Current therapeutic and preventive measures are palliative, not curative. The definitive cure of ARVC/D will be based on the discovery of the molecular mechanisms that are involved in the etiology and pathogenesis of the disease.
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